Thank you. Listen to this article using the player above. ✖

New Study Reveals Genetic Factors in Frontal Fibrosing Alopecia

Recent research published in JAMA Dermatology uncovers a significant genetic interaction that increases the risk of frontal fibrosing alopecia (FFA). Scientists at King’s College London identified specific genetic variations in two genes, ERAP1 and those in the major histocompatibility complex (MHC), that when combined, elevate the likelihood of developing FFA.

Understanding Frontal Fibrosing Alopecia

FFA is a distressing skin condition characterized by inflammation, scarring, and irreversible hair loss. Primarily affecting the frontal part of the scalp, FFA is a complex condition influenced by both genetic and environmental factors. As global cases of FFA rise, understanding its underlying mechanisms is crucial for developing effective treatments.

The Genetic Link

The study conducted a meta-analysis of four groups of women suffering from FFA across the United Kingdom and Europe, focusing on the MHC region. This cluster of genes plays a key role in immune system functioning by helping to recognize foreign substances. Researchers discovered that certain genetic changes in ERAP1 interact with MHC genes to increase the risk of developing FFA. This genetic interaction, known as epistasis, is unique in human genetics, where the presence of one gene modifies the effect of another.

Historical Perspective

Previous studies have linked genetic variants in the ERAP1 and ERAP2 genes to survival during the Black Death, a devastating plague that affected Europe in the 1300s. While these variants were beneficial in protecting against infections back then, they may also make individuals more susceptible to certain autoimmune diseases, including FFA. This study provides concrete evidence that such genetic traits can influence risk factors for FFA.

Implications for Treatment and Prevention

He added: “Since the disease was first described in 1994, the number of cases has skyrocketed. Our new findings not only provide deeper insight into the autoimmune nature of FFA but also point towards directions for further investigation and drug development.”

The study authors envision the possibility of a predictive genetic test for FFA risk, which could help medical professionals identify individuals at higher risk of developing the condition. Furthermore, this research may open up new avenues for targeted therapies, particularly those that act on the ERAP1 gene.

Support for Future Research

Phil Brady, Chief Operating Officer at the British Skin Foundation, praised the study, stating, “This research marks a major breakthrough in our understanding of frontal fibrosing alopecia and why it affects some people more than others. This condition can be incredibly distressing, and learning how genes interact to influence risk could lead to better methods for predicting and treating it in the future. We’re proud to support studies like this that bring real hope to those affected.”

The research was funded by the British Skin Foundation, with additional support from The Medical Research Council and clinical sites across the UK and Europe.

Conclusion and Future Directions

This study illuminates the intricate genetic basis of FFA, offering invaluable insights into its autoimmune causes. By elucidating these genetic interactions, scientists are inching closer to developing more accurate predictive models and innovative treatment strategies. As investigations into FFA continue, experts hope to bring relief to the many individuals affected by this condition.

Reference

Rayinda T, Dand N, McSweeney SM, et al. Epistasis of ERAP1 with 4 major histocompatibility complex class I alleles in frontal fibrosing alopecia: A genome-wide association study meta-analysis. JAMA Dermatology. 2025. doi: 10.1001/jamadermatol.2024.6434